explore -WSS

explore

author：explore 2025-10-06 08:57:18 - browse：5

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Why Novartis is going to walk from its acquisition of MorphoSys

focus

WSS

Global cancer cases to surge 77% by 2050, WHO report says

Texas Medical Board asked to define abortion emergency exception

Removing probiotics from the NICU could threaten preemies' health

Study: New antibiotic targets gonorrhea as well as last existing drug

Devoted Health’s losses in Medicare Advantage persist

Surgery pushed Ben Carson to fame

hotspot

explore

leisure time

How to save PrEP access — and even expand it

UCSF medical school apologizes for unethical prisoner experiments

BioMarin wins approval for gene therapy to treat hemophilia A

Updated Covid vaccine has 54% effectiveness, new study suggests

Cancer drug shortages should be causing more outrage

A clever new way to fix Medicaid and graduate medical education

The cancer drug shortage isn’t new — and neither are the solutions

Medicare solvency divides Republicans at the presidential debate

Walensky prepares to leave CDC — and Congress — behind

Excited delirium, Elijah McClain, and emergency physicians

entertainment

Updated Covid vaccine has 54% effectiveness, new study suggests

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Cano Health’s bankruptcy is a warning for Medicare Advantage

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Extreme heat events are a public health emergency

Will General Catalyst be the first of many hospital takeovers?

explore

focus

entertainment

leisure time